Opus Genetics 過去の業績

過去基準チェック /06

Opus Geneticsの収益は年間平均-11.4%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間33.8% 16%割合で増加しています。

主要情報

-11.42%

収益成長率

40.73%

EPS成長率

Biotechs 業界の成長	17.04%
収益成長率	16.03%
株主資本利益率	n/a
ネット・マージン	-892.36%
前回の決算情報	31 Mar 2026

Recent updates

分析記事 • Feb 07

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

Opus Genetics, Inc. ( NASDAQ:IRD ) shareholders have had their patience rewarded with a 43% share price jump in the...

分析記事 • Dec 11

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 27% in...

分析記事 • Sep 09

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 31% in...

分析記事 • Jul 11

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc.'s ( NASDAQ:IRD ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right now...

分析記事 • May 19

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

Investors in Opus Genetics, Inc. ( NASDAQ:IRD ) had a good week, as its shares rose 7.4% to close at US$1.02 following...

分析記事 • Apr 09

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Opus Genetics, Inc. ( NASDAQ:IRD ) share price has dived 25% in the last...

分析記事 • Aug 19

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Celebrations may be in order for Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders, with the analysts delivering a...

分析記事 • Jul 24

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders have had their patience rewarded with a 30% share price jump in the...

分析記事 • Jul 12

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

分析記事 • May 02

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) share price has dived 26% in the last...

分析記事 • Mar 15

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders that were waiting for something to happen have been dealt a blow...

収支内訳

Opus Genetics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:IRD 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 26	12	-107	22	3
31 Dec 25	14	-50	22	0
30 Sep 25	15	-68	24	0
30 Jun 25	15	-58	22	0
31 Mar 25	14	-59	20	0
31 Dec 24	11	-58	18	0
30 Sep 24	8	-27	14	0
30 Jun 24	16	-14	13	0
31 Mar 24	19	-11	14	0
31 Dec 23	19	-10	12	0
30 Sep 23	57	29	11	0
30 Jun 23	45	19	10	0
31 Mar 23	42	19	8	0
31 Dec 22	40	18	7	0
30 Sep 22	0	-22	7	0
30 Jun 22	0	-22	7	0
31 Mar 22	1	-24	8	0
31 Dec 21	1	-57	8	0
30 Sep 21	1	-69	8	0
30 Jun 21	0	-66	7	0
31 Mar 21	0	-61	4	0
31 Dec 20	0	-25	3	0
30 Sep 20	0	-8	2	1
30 Jun 20	0	-9	2	2
31 Mar 20	0	-8	2	2
31 Dec 19	0	-6	2	2

質の高い収益: IRDは現在利益が出ていません。

利益率の向上: IRDは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: IRDは利益が出ておらず、過去 5 年間で損失は年間11.4%の割合で増加しています。

成長の加速: IRDの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IRDは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。

株主資本利益率

高いROE: IRDの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/26 14:20
終値	2026/05/26 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Opus Genetics, Inc. 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。15

アナリスト	機関
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2025 earnings: EPS misses analyst expectations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Consensus EPS estimates fall by 77%

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Opus Genetics Completes Enrollment In Cohort 1 Of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces Fda Acceptance of Opgx-Lca5 into Rare Disease Evidence Principles (Rdep) Program

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLC

High number of new directors

Consensus EPS estimates fall by 19%, revenue upgraded

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Price target increased by 7.5% to US$9.50

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 14% to US$8.83

Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

New minor risk - Share price stability

Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa

Independent Chairman recently bought US$324k worth of stock

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Consensus EPS estimates fall by 16%, revenue upgraded

Third quarter 2025 earnings: EPS misses analyst expectations

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Price target increased by 13% to US$6.80

New major risk - Revenue and earnings growth

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Consensus revenue estimates decrease by 18%, EPS upgraded

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

New major risk - Financial position

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Consensus revenue estimates increase by 16%

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

過去基準チェック /06